Herry Herman

Herry Herman

Auto-generated profile, based on publicly available information

Herry Herman

Department of Orthopaedics and Traumatology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2023 in Current Aging Science
Verified
Journal Article
Closed access
PDF file
ACAndreas Christoper
Andreas Christoper
HHHerry Herman
Herry Herman
RARizky Abdulah
Rizky Abdulah
FZFelix Zulhendri
Felix Zulhendri
ASArdo Sanjaya
Ardo Sanjaya
RLRonny Lesmana
Ronny Lesmana
Background: Dementia is a neurocognitive disorder associated with the aging brain and mainly affects the hippocampus and cerebral cortex. The Hippo signaling pathway and autophagy proteins have been found to be perturbed in the brain affected by dementia processes. Objective: This systematic review aims to elaborate on the involvement of the Hippo signaling pathway and autophagy in modulating the progression and severity of dementia in aging. Methods: Searches were conducted on MEDLINE, Google Scholar, Scopus, and Web of Science databases. Results: The Hippo signaling pathway is dependent upon the transcriptional co-activator YAP/TAZ, which forms complexes with TEAD in the nucleus in order to maintain cell homeostasis. When the expression YAP/TAZ is reduced, transcriptional repression-induced atypical cell death, ballooning cell death, and necrosis will consequently occur in the neurons. Moreover, the autophagic proteins, such as LC3, ATG proteins, and Beclin, are reduced, resulting in the disruption of autophagosome formation and accumulation and the spread of misfolded proteins in the brain suffering from dementia. Conclusion: The impairment of the Hippo signaling pathway and autophagy in the dementia process in aging should be considered since it might predict the severity, treatment, and prevention of dementia.

13 January 2026 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
ACAndreas Christoper
Andreas Christoper
HHHerry Herman
Herry Herman
RARizky Abdulah
Rizky Abdulah
FZFelix Zulhendri
Felix Zulhendri
Milena P. PopovaMilena P. Popova
Milena P. Popova
RLRonny Lesmana
Ronny Lesmana
Background: Metabolic syndromes, including obesity, dyslipidemia, and diabetes mellitus, can exacerbate inflammation-induced liver damage, which is associated with high-fat diets (HFD) and sedentary lifestyles. The substantial hypolipidemic and anti-inflammatory properties of propolis extract can potentially reduce hepatic inflammation and prevent the progression of liver damage. This study aims to investigate the role of Indonesian propolis extract in reducing hepatic inflammation after dyslipidemia and hyperglycemia. Methods: The experiment started with feeding HFD to the rats for 12 weeks, then a daily dosage of 300 mg/kg BW of propolis extract was administered via gavage for 9 weeks. Body weight, liver index, and blood biochemical analysis were conducted to determine the pharmacodynamic evaluation of propolis extract. The expression of inflammatory cytokines was investigated in the liver tissue. The correlation and regression analysis assessed the relationship between dyslipidemia, hyperglycemia, and hepatic inflammation. Results: Nine weeks of propolis extract supplementation significantly decreased body weight and liver index. Propolis also improves blood profile by reducing cholesterol, triglycerides, LDL-C, and glucose levels and increasing HDL-C levels. The expression of hepatic inflammatory cytokines such as IL-1β, IL-6, and TNF-α was decreased in the HFD group after propolis administration. A significant moderate to strong correlation (0.56–0.94) was found between the lipid profile, glucose levels, and hepatic inflammation. The lipid profile represented approximately 84.6%, 49.9%, and 68.7% of the hepatic inflammatory cytokine expression variation of IL-1β, IL-6, and TNF-α. Conclusion: Based on current evidence, Indonesian propolis alleviated hepatic inflammation by improving dyslipidemia and hyperglycemia after a prolonged high-fat diet in vivo. Therefore, further clinical studies are warranted to substantiate its complementary role in metabolic or inflammatory conditions. Clinical trial number: Not Applicable.